Table 2 Characteristics of screening serum sets
1st sampling test | Validation test | |
|---|---|---|
Sampling periods | 1998-2005 | 2005-2008 |
No. of patients | 128 | 115 |
Healthy donors, n (%) | 56 (43.8) | 48 (41.7) |
Age (mean ± SD), range | 48.1 ± 18.3, 16-76 | 51.3 ± 15.2, 16-76 |
Low-grade glioma, n(%) | 40 (31.3) | 42 (36.5) |
Age (mean ± SD), range | 45.8 ± 14.8, 20-74 | 44.2 ± 14.1, 22-78 |
Pilocytic astrocytoma, n (%) | 2 (5.0) | 4 (9.5) |
Diffuse astrocytoma, n (%) | 18 (45.0) | 15 (35.7) |
Oligodendroglioma, n (%) | 16 (40.0) | 19 (45.2) |
Oligoastrocytoma, n (%) | 3 (7.5) | 1 (2.4) |
Ependymoma, n (%) | 1 (2.5) | |
Ganglioglioma, n (%) | 3 (7.1) | |
High-grade glioma, n (%) | 32 (25.0) | 25 (21.7) |
Age (mean ± SD), range | 49.7 ± 18.3, 8-78 | 49.8 ± 15.5, 28-78 |
Glioblastoma, n (%) | 24 (75.0) | 17 (68.0) |
Anaplastic astrocytoma, n (%) | 5 (15.6) | 3 (12.0) |
Anaplastic oligodendroglioma, n (%) | 2 (6.3) | 2 (8.0) |
Anaplastic oligoastrocytoma, n (%) | 1 (3.1) | 1 (4.0) |
Anaplastic ependymoma, n (%) | 1 (4.0) | |
Choroid plexus carcinoma, n (%) | 1 (4.0) |